WuXi Biologics (Cayman) Inc. (02269.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	43.5B	21.8B	18.7B	17.0B	15.3B
Cost of Revenue	23.8B	11.8B	11.0B	10.2B	8.5B
Gross Profit	19.7B	10.0B	7.7B	6.8B	6.7B
Operating Expenses
R&D Expense	1.7B	860.1M	766.4M	792.6M	682.8M
SG&A Expense	4.9B	2.5B	2.1B	1.8B	1.4B
General & Admin Expense	3.5B	1.7B	1.7B	1.5B	1.3B
Selling & Marketing Expense	1.2B	608.8M	473.6M	294.0M	162.9M
Other Expenses	(340.9M)	65.2M	(236.5M)	(204.2M)	266.8M
Total Operating Expenses	6.2B	3.4B	2.7B	2.4B	2.4B
Cost and Expenses	30.0B	15.2B	13.7B	12.6B	10.9B
Operating Income (EBIT)	13.5B	6.6B	5.0B	4.5B	4.3B
Non-Operating
Interest Income	889.3M	384.4M	350.4M	219.2M	107.5M
Interest Expense	260.1M	139.4M	157.6M	158.5M	64.4M
Net Interest Income	629.3M	245.0M	192.8M	60.7M	43.1M
Other Non-Op Income/Expense	(19.8M)	617.2M	(139.4M)	(276.4M)	1.0B
Non-Operating Income (excl Interest)	(24.9M)	(6.8M)	(18.2M)	117.9M	(8.2M)
EBT (Pre-Tax Income)	13.5B	7.3B	4.8B	4.2B	5.4B
Income Tax Expense	2.7B	1.5B	889.0M	603.2M	807.9M
Bottom Line
Net Income	9.2B	4.9B	3.4B	3.4B	4.4B
Earnings from Cont. Ops	10.8B	5.7B	3.9B	3.6B	4.5B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	9.1B	4.9B	3.4B	3.4B	4.4B
Per Share
Basic EPS	HK$2.21	HK$1.16	HK$0.82	HK$0.82	HK$1.06
Diluted EPS	HK$2.16	HK$1.16	HK$0.78	HK$0.77	HK$1.01
Revenue Per Share	HK$10.62	HK$5.22	HK$4.57	HK$4.09	HK$3.66
Shares
Basic Shares Outstanding	4.1B	4.2B	4.1B	4.2B	4.2B
Diluted Shares Outstanding	4.2B	4.2B	4.2B	4.3B	4.4B
Profitability Metrics
EBITDA	16.2B	7.9B	6.4B	5.5B	6.2B
D&A	2.7B	1.3B	1.4B	1.2B	800.7M
EBIT	13.5B	6.6B	5.0B	4.3B	5.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026